title: The formulation of recombinant factor IX: stability, robustness, and convenience.
abstract: A lyophilized recombinant factor IX (rFIX) formulation has been developed that is stable and contains no preservatives. No blood or plasma products are used in the production or formulation of rFIX. The formulation contains 10 mmol/L histidine, 0.26 mol/L glycine, 1% sucrose, and 0.005% polysorbate-80 (pH 6.8). Polysorbate-80 acts as a protectant for the protein from freezing-induced damage (eg, aggregation). Sucrose provides protection to the protein in the freeze-dried state. Glycine provides for a high-quality cake morphology. Histidine provides optimal buffering stability at the desired pH and minimizes aggregate formation upon storage in the lyophilized state. This optimized combination of excipients provides a high degree of long-term stability, as demonstrated by a variety of analytical methods, including clotting assays, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), isoelectric focusing (IEF), size-exclusion chromatography (SEC), peptide mapping, oligosaccharide fingerprinting, and reverse-phase high-performance liquid chromatography (HPLC). The rFIX product is easy to reconstitute and demonstrates excellent stability in solution after reconstitution.
authors.affiliation: Genetics Institute, Andover, MA 01810, USA.
authors.forename: L
authors.initials: L
authors.lastname: Bush
authors.forename: C
authors.initials: C
authors.lastname: Webb
authors.forename: L
authors.initials: L
authors.lastname: Bartlett
authors.forename: B
authors.initials: B
authors.lastname: Burnett
mesh_terms: D002626:Chemistry, Pharmaceutical / Q000592:standards*; D005164:Factor IX / Q000592:standards* / Q000627:therapeutic use; D002836:Hemophilia B / Q000188:drug therapy; D006801:Humans; D011994:Recombinant Proteins / Q000592:standards / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; D005164:Factor IX